Abivax First-Half 2017 Financial Results And Update

Published: Sep 22, 2017

PARIS, Sept. 20th, 2017 at 6:30p.m. CEST – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, today announced its 2017 half-year financial results, as of June 30, 2017, and provides an update on its progress during the first half of 2017. The financial statements for the first half of 2017, approved by the company’s board of directors on Sept. 18, 2017, have been audited and the certification report is being prepared by the Company’s external auditors.

Back to news